Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  An, Ningfei ^a   Kraft, Andrew S ^a   Kang, Yubin ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; Hematopoietic stem cell transplantation; Hematopoietic stem cells; Knockout mouse; Pim kinase; Proliferation; Serine threonine kinase

Indexed keywords

BROXURIDINE; CASPASE 3; KI 67 ANTIGEN; PROTEIN KINASE; PROVIRAL INSERTION IN MURINE LYMPHOMA KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ASSAY; BONE MARROW CELL; CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; EX VIVO STUDY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; MALE; MICROCYTOSIS; MOUSE; NONHUMAN; PHENOTYPE; THROMBOCYTE COUNT;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; BROMODEOXYURIDINE; CELL AGING; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; MALE; MICE; MICE, KNOCKOUT; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-PIM-1; SURVIVAL RATE;

EID: 84872979769     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-12     Document Type: Article

References (33)

1. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, van Wezenbeek P, Melief C, Berns A, Cell 1984 37 1 141 150 10.1016/0092-8674(84)90309-X 6327049 (Pubitemid 14079845)
2. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. Breuer ML, Cuypers HT, Berns A, EMBO J 1989 8 3 743 748 2721500
3. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, Berns A, Nat Genet 2002 32 1 153 159 10.1038/ng950 12185366 (Pubitemid 34977211)
4. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, Berns A, Mol Cell Biol 2004 24 13 6104 6115 10.1128/MCB.24.13.6104-6115.2004 15199164 (Pubitemid 38787993)
5. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J, Haematologica 2010 95 6 1004 1015 10.3324/haematol. 2009.017079 20145274
6. Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Eichmann A, Yuan L, Breant C, Alitalo K, Koskinen PJ, Oncogene 2000 19 9 1215 1224 10.1038/sj.onc.1203355 10713710 (Pubitemid 30157552)
7. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS, BMC Cell Biol 2006 7 1 10.1186/1471-2121-7-1 16403219 (Pubitemid 43256852)
8. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A, Cell 1989 56 4 673 682 10.1016/0092-8674(89)90589-8 2537153 (Pubitemid 19065532)
9. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A, Oncogene 1997 15 10 1133 1141 10.1038/sj.onc.1201288 9294606 (Pubitemid 27429616)
10. In vivo analysis of Pim-1 deficiency. Laird PW, van der Lugt NM, Clarke A, Domen J, Linders K, McWhir J, Berns A, Hooper M, Nucleic Acids Res 1993 21 20 4750 4755 10.1093/nar/21.20.4750 8233823 (Pubitemid 23312750)
11. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB, Blood 2005 105 11 4477 4483 10.1182/blood-2004-09-3706 15705789 (Pubitemid 40720797)
12. Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, J Exp Med 2009 206 9 1957 1970 10.1084/jem.20082074 19687226
13. Using quantitative real-time PCR to determine donor cell engraftment in a competitive murine bone marrow transplantation model. An N, Kang Y, J Vis Exp 2013 In press
14. Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. Kang Y, Chen BJ, Deoliveira D, Mito J, Chao NJ, PLoS One 2010 5 6 11316 10.1371/journal.pone. 0011316 20596257
15. Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Adolfsson J, Borge OJ, Bryder D, Theilgaard-Monch K, Astrand-Grundstrom I, Sitnicka E, Sasaki Y, Jacobsen SE, Immunity 2001 15 4 659 669 10.1016/S1074-7613(01)00220-5 11672547 (Pubitemid 33016450)
16. Chimerism analysis in sex-mismatched murine transplantation using quantitative real-time PCR. Byrne P, Huang W, Wallace VM, Shean MK, Zhang Z, Zhong Q, Theodossiou C, Blakesley H, Kolls JK, Schwarzenberger P, Biotechniques 2002 32 2 279-280 282-274, 286 11848403
17. Expansion of hematopoietic stem cells for transplantation: current perspectives. Schuster JA, Stupnikov MR, Ma G, Liao W, Lai R, Ma Y, Aguila JR, Exp Hematol Oncol 2012 1 1 12 10.1186/2162-3619-1-12 23210618
18. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A, Proc Natl Acad Sci U S A 1989 86 22 8857 8861 10.1073/pnas.86.22.8857 2682662 (Pubitemid 20010324)
19. Evidence that the Pim1 kinase gene is a direct target of HOXA9. Hu YL, Passegue E, Fong S, Largman C, Lawrence HJ, Blood 2007 109 11 4732 4738 10.1182/blood-2006-08-043356 17327400 (Pubitemid 46827765)
20. Self-renewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-3. Aksoy I, Sakabedoyan C, Bourillot PY, Malashicheva AB, Mancip J, Knoblauch K, Afanassieff M, Savatier P, Stem Cells 2007 25 12 2996 3004 10.1634/stemcells.2007-0066 17717068 (Pubitemid 350294424)
21. Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death. Pircher TJ, Zhao S, Geiger JN, Joneja B, Wojchowski DM, Oncogene 2000 19 32 3684 3692 10.1038/sj.onc.1203684 10951575 (Pubitemid 30608490)
22. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation. Nosaka T, Kitamura T, Exp Hematol 2002 30 7 697 702 10.1016/S0301-472X(02)00808- 1 12135666 (Pubitemid 34831689)
23. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Lilly M, Kraft A, Cancer Res 1997 57 23 5348 5355 9393759 (Pubitemid 27516373)
24. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y, J Biol Chem 1999 274 26 18659 18666 10.1074/jbc.274.26.18659 10373478 (Pubitemid 29293863)
25. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Moroy T, Int J Biochem Cell Biol 2006 38 3 430 443 10.1016/j.biocel.2005.10.010 16356754 (Pubitemid 41821890)
26. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N, Cancer Res 2008 68 13 5076 5085 10.1158/0008-5472.CAN-08-0634 18593906
27. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ, FEBS Lett 2004 571 1-3 43 49 15280015 (Pubitemid 38992921)
28. PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis. Gu JJ, Wang Z, Reeves R, Magnuson NS, Oncogene 2009 28 48 4261 4271 10.1038/onc.2009.276 19749799
29. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS, Cancer Biol Ther 2009 8 9 846 853 10.4161/cbt.8.9.8210 19276681
30. The Pim protein kinases regulate energy metabolism and cell growth. Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, Smith CD, Kraft AS, Proc Natl Acad Sci U S A 2011 108 2 528 533 10.1073/pnas.1013214108 21187426
31. The PIM kinases in hematological cancers. Alvarado Y, Giles FJ, Swords RT, Expert Rev Hematol 2012 5 1 81 96 10.1586/ehm.11.69 22272708
32. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Merchant A, Joseph G, Wang Q, Brennan S, Matsui W, Blood 2010 115 12 2391 2396 10.1182/blood-2009-09-241703 20107231
33. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, Ramsey MR, Jin J, Wong KK, Su L, J Clin Invest 2010 120 7 2528 2536 10.1172/JCI41402 20577054